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Background:  The  exact  duration  of  antibody  persistence  to hepatitis  A and  B and  the need  for booster
dosing  following  primary  immunisation  remains  undeﬁned.  A long-term  study  was  designed  to  follow
antibody  persistence  and  immune  memory  on  an  annual  basis  for  up  to  15 years  following  vaccination
during  adolescence.
Methods:  Subjects  received  a combined  hepatitis  A  and  B  vaccine  (TwinrixTM, GSK  Vaccines,  Belgium)  at
12–15  years  of  age,  either  as 2-dose  of the  adult  formulation  or 3-dose  of  the  paediatric  formulation.
Blood  samples  were  taken  every  year  thereafter  to  assess  antibody  persistence  and  immune  memory  to
hepatitis  A and  B.  Antibodies  to hepatitis  A virus  (anti-HAV)  and  hepatitis  B surface  antigen  (anti-HBs)
were  measured  at Years  11–15.  At Year  15  immune  memory  was further  assessed  by  measuring  the
anamnestic  response  to a challenge  dose  of  the  monovalent  vaccine,  which  was  administered  to subjects
whose  antibody  concentrations  fell  below  the  pre-deﬁned  cut-offs  (anti-HAV:  <15  mIU/mL;  anti-HBs:
<10  mIU/mL).
Results:  209  subjects  returned  for follow-up  at Year  15 of  whom  162 were  included  in the  long-term
according-to-protocol  immunogenicity  cohort.  All  subjects  remained  seropositive  for  anti-HAV  anti-
bodies,  while  81.1%  and  81.8%  still  had  anti-HBs  antibodies  ≥10  mIU/mL  in  the  2- and  3-dose  groups,
respectively.  Following  hepatitis  B vaccine  challenge  dose  administration  to 19  subjects,  all  except  one
in  the  3-dose  group,  mounted  a robust  anamnestic  response.  The  safety  and  reactogenicity  proﬁle  of the
hepatitis  B challenge  was consistent  with  previous  experience.
Conclusion:  Immunity  to  hepatitis  A  and  B persists  15 years  after  adolescent  vaccination  with  a  combined
hepatitis  A  and  B vaccine.  Highly  effective  anamnestic  response  indicates  that  a  booster  dose  should  not
be required  for  15 years  after  primary  vaccination.
Trial registration:  http://www.clinicaltrials.gov NCT00875485.
ublis© 2016  The  Authors.  PAbbreviations: HAV, hepatitis A virus; HBV, hepatitis B virus; HBs, hepatitis B
urface antigen; anti-HBs, antibodies to hepatitis B surface antigen; anti-HAV, anti-
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ssay; GMC, geometric mean concentration; IU, International units; LT-ATP, long-
erm-according to protocol; EL.U, ELISA Units.
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1. Introduction
Both hepatitis A virus (HAV) and hepatitis B virus (HBV) infec-
tions have a worldwide distribution and impose a considerable
healthcare burden; with signiﬁcant morbidity and mortality [1–3].
Vaccination is the most effective and safe method of conferring
long-term protection against both of these viruses [4] and has
resulted in a steady reduction in infections worldwide [5]. Although
monovalent vaccines against both HAV and HBV are known to be
immunogenic and safe [6]; a dual vaccination against both viruses
is highly desirable due to the considerable overlap of risk factors
and areas of high-endemicity for both diseases [7].
A combined hepatitis A and B vaccine (TwinrixTM Junior, GSK
Vaccines, Belgium) which contains 360 ELISA Units (EL.U) of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nactivated HAV antigen and 10 g of hepatitis B surface antigen
HBs) is licensed as a 3-dose regimen, for administration at 0, 1
nd 6 months to children aged 1–15 years. The adult formulation
TwinrixTM Adult; containing 720 EL.U of inactivated HAV antigen
nd 20 g of HBs antigen) is licensed for vaccinating children aged
–11 years, as a 2-dose regimen administered at 0 and 6 months.
his 2-dose schedule is also licensed as AmbirixTM (GSK Vaccines,
elgium) in some countries [8].
The safety, immunogenicity and long-term antibody persis-
ence of the combined hepatitis A and B vaccine are comparable to
hose of the respective monovalent vaccines [9,10]. Further, long-
erm antibody persistence lasting for up to 17 years following the
onventional 3-dose regimen in adults has been established [11].
owever, the exact duration of protection and whether booster
oses of vaccine are needed to maintain long-term immunity
emains debatable, particularly for HBV vaccination [6,12].
In 1998, a randomised clinical trial comparing the safety and
mmunogenicity of primary vaccination of 12–15 years old adoles-
ents with either 2 doses of the adult formulation or 3 doses of
he paediatric formulation was initiated. After 24 months, the non-
nferiority of the two regimens with respect to immunogenicity was
emonstrated [10]. After 10 years of follow-up, the two  regimens
onferred similar long-term protection against hepatitis A and B
8]. The present study re-assessed persistence up to 15 years after
rimary vaccination. In addition, immune memory was assessed at
ear 15 by measuring the anamnestic response to a challenge dose
f either monovalent vaccine administered in subjects whose cor-
esponding antibody levels had dropped below pre-deﬁned cut-offs
anti-HAV: <15 mIU/mL; anti-HBs: <10 mIU/mL) during the long-
erm follow-up.
. Methods
.1. Study design and population
Full details on the study design have been previously published
8,10]. This long-term follow-up study concluded in June 2014
NCT00875485) and the subjects remained in the group they were
andomised to 15 years earlier. Subjects who completed 10 years
ollow-up were invited to attend further annual follow-up visits
rom Year 11 to 15. If, during this long-term follow-up period the
ubjects had anti-HAV concentrations ≤15 mIU/mL and/or anti-HBs
oncentration below ≤10 mIU/mL, they were invited to receive a
hallenge dose of monovalent hepatitis A (HavrixTM, GSK Vaccines,
elgium) and/or hepatitis B (Engerix-BTM, GSK Vaccines, Belgium)
accines, respectively. Only subjects who took part in the primary
tudy and had consented to participate in the long-term exten-
ion were included in the follow-up. The exclusion criteria from
he primary study remained the same for the challenge dose, with
he addition of pregnant or lactating females. Written informed
onsent was obtained from all the subjects before initiating any
tudy related procedure. The study was conducted according to
ood Clinical Practice guidelines and the Declaration of Helsinki,
ith necessary approvals from the relevant Ethics Committees.
.2. Assessment of immunogenicity
Blood samples were collected annually until Year 15 after
rimary vaccination. Anti-HAV antibody concentrations were mea-
ured at all time-points using a commercial enzyme immunoassay
EnzygnostTM Anti-HAV, Siemens Healthcare, Marburg, Germany,
ut-off: 15 mIU/mL). The anti-HBs concentrations were mea-
ured using a commercial chemiluminescence assay (ADIVA
entaurTM Anti-HBs, Siemens Healthcare, Marburg, Germany, cut-
ff: 6.2 mIU/mL). (2016) 2686–2691 2687
2.3. Assessment of safety
The safety assessment included retrospective reporting of seri-
ous adverse events (SAEs) by subjects during the entire follow-up
period.
All and grade 3 solicited local (pain, redness, swelling) and
general (fatigue, gastrointestinal symptoms, headache, fever)
symptoms were recorded for 4 days after the challenge dose and
SAEs were recorded for 30 days post-challenge.
2.4. Statistical analysis
The primary analysis of immunogenicity was performed on the
long-term according-to-protocol (LT-ATP) cohort, which included
all subjects who returned for blood sampling at deﬁned time-points
and met  all eligibility criteria. The analyses for the challenge dose
were performed on the LT-ATP cohort, which included all evaluable
subjects who  had received the challenge dose and had available
data for the immunogenicity endpoint at the post-challenge dose
time-point.
The percentage of subjects who were seropositive for anti-HAV
and had anti-HBs antibodies ≥10 mIU/mL; with their correspond-
ing geometric mean concentrations (GMCs) from one month after
their last vaccination dose to Year 15 were tabulated with 95% con-
ﬁdence intervals (CI). GMCs were calculated as the antilog of the
mean of log-transformed anti-HAV and anti-HBs concentrations.
The anti-HBs anamnestic response was  deﬁned as anti-HBs anti-
body concentrations ≥10 mIU/mL one month post-challenge in
subjects who  were seronegative pre-challenge or ≥4-fold increase
in anti-HBs antibody concentrations one month post-challenge
dose in subjects who were seropositive at the pre-challenge time-
point. The percentage of subjects with an anamnestic response to
the hepatitis B challenge dose, percentage of subjects with anti-
HBs concentrations ≥10 mIU/mL, ≥100 mIU/mL and corresponding
GMCs were tabulated with 95% CIs pre- and post-challenge dose.
The statistical analyses were performed using the SAS (Statisti-
cal Analysis Software, SAS Institute Inc., Cary, NC, United States).
3. Results
3.1. Study population
The number of subjects included in the primary study, those who
returned at each of the long-term follow-up time-points, and those
included in the LT-ATP cohort are presented in Fig. 1. Of the 300 sub-
jects who  participated in the primary study, 209 subjects returned
for the Year 15 follow-up, of whom 162 subjects (2-dose group,
N = 74; 3-dose group, N = 88) were included in the LT-ATP cohort.
The demographic characteristics in both study groups (3-dose and
2-dose groups) were similar at the 15-year follow-up time-point;
the mean age of subjects was 28.4 ± 1.09 years and 55.6% were male.
3.2. Immunogenicity
The non-inferiority of a 2-dose regimen of the adult formu-
lation to a 3-dose regimen of the paediatric formulation of the
combined hepatitis A and B vaccine has been previously estab-
lished [8]. Fifteen years after primary vaccination, all subjects
in both groups remained seropositive for anti-HAV antibodies.
81.1% subjects in the 2-dose and 81.8% in the 3-dose groups had
anti-HBs antibody concentrations ≥10 mIU/mL (Fig. 2). At year
15, the anti-HAV antibody GMCs (2-dose: 387.5 mIU/mL; 3-dose:
299.4 mIU/mL) and anti-HBs antibody GMCs (2-dose: 87.2 mIU/mL;
3-dose: 69.6 mIU/mL) were similar in both groups (Fig. 3).
2688 J. Beran et al. / Vaccine 34 (2016) 2686–2691
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ewly eliminated subjects: subjects eliminated during current blood sampling vis
ast  visit.
The evolution curves for anti-HAV and anti-HBs antibody GMCs
ere also similar in both groups, with plateaus observed from Years
0 to 15 (Fig. 3).
.3. Challenge dose
No subject received a challenge dose of monovalent HAV vac-
ine as all remained seropositive for anti-HAV at Year 15. Nineteen
ubjects (2-dose group, N = 8; 3-dose group, N = 11) had anti-HBs
10 mIU/mL during Years 11–15 and therefore received a challenge
ose of monovalent hepatitis B vaccine. One month post-challenge
ose, all subjects in the 2-dose and 90.9% (10/11) subjects in
he 3-dose group mounted an anamnestic response for anti-HBsiously eliminated subjects: subjects eliminated previously between ﬁrst visit and
antibodies. Compared with pre-challenge, the post-challenge GMC
was 900-fold higher in the 2-dose group (GMC: 3022.8 [95% CI:
407.8–2240.5]) and 300-fold higher in the 3-dose group (GMC:
1433.1 [95% CI: 324.4–6328.9]) (Fig. 4).
3.4. Safety and reactogenicity
No vaccine-related SAEs were reported during the entire study
period. Following the challenge dose, pain at the injection site (2-
dose group: 5/8; 3-dose group: 4/11) and fatigue (2-dose group:
3/8; 3-dose group: 3/11) were the most frequently reported
solicited local and general symptoms, respectively, during the
4-day follow-up period. No grade 3 solicited local and general
J. Beran et al. / Vaccine 34 (2016) 2686–2691 2689
Fig. 2. Percentage of subjects seropositive for anti-HAV and with anti-HBs antibody concentrations ≥10 mIU/mL during the long-term follow-up (LT-ATP cohort).
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i,  month; Y, year. The anti-HBs concentrations up to Year 8 time-point were test
ears  9 and 10 a validated equivalent in house ELISA with an assay cut-off of 3.3 m
mmunosorbent assay (CLIA) anti-HBs assay with a cut-off of 6.2 mIU/mL.
ymptoms were reported. One subject experienced a SAE (spon-
aneous abortion) during the study; it was not considered to be
accine-related.
. Discussion
This article presents the results of a 15-year follow-up study
f the combined hepatitis A and B vaccine administered during
dolescence (12–15 years of age) either as 2 doses of the adult for-
ulation or 3 doses of the paediatric formulation. As reported at
ear 10 follow-up time-point [8], no difference was observed in
ong-term immunity between the groups.
ig. 3. Anti-HAV and anti-HBs antibody GMC  evolution during long-term follow-up (LT-A
,  month; Y, year. The anti-HBs concentrations up to the Year 8 time-point were tested 
n-house ELISA with an assay cut-off of 3.3 mIU/mL was used. The sera from Year 11 onwng a commercial AUSAB/Abbott Enzyme-linked immunosorbent assay (ELISA). At
L was used. The sera from Year 11 onwards were tested with chemiluminescence
The results of our study, in which all subjects in both group
remained seropositive for anti-HAV after 15 years, are consistent
with previous studies where the persistence of immune memory
was observed up to 17 years after adult vaccination with the com-
bined hepatitis A and B vaccine [11] and up to 20 years after the
monovalent hepatitis A vaccine [13]. Similar observations have
been reported 10 years after primary vaccination with 2 doses of
monovalent hepatitis A vaccine administered in childhood with
over 95% seropositivity being maintained [14,15]. Excellent long-
term immunogenicity using the 2-dose schedule in children and
adolescents, and the plateauing anti-HAV GMC levels indicate that
the protective antibody levels may  persist even longer [16].
TP cohort).
using a commercial AUSAB/Abbott ELISA. At Years 9 and 10 a validated equivalent
ards were tested with CLIA anti-HBs assay with a cut-off of 6.2 mIU/mL.
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At least 81% subjects in both groups maintained anti-HBs anti-
ody concentrations ≥10 mIU/mL at Year 15, which is only slightly
ower than our observation at Year 10 (85%) [8]. These results are
n line with a previous study from Canada, where seroprotection
ates of 76.7% were reported 15 years after primary vaccination of
dolescents with 3 doses of monovalent hepatitis B vaccine [17].
imilar results have been observed following the administration of
 doses of combined hepatitis A and B vaccine in adults where 89.3%
f subjects remained seroprotected for anti-HBs antibody 15 years
ost vaccination [18].
As 19 subjects received a challenge dose of monovalent hepati-
is B vaccine at Year 15, we were able to evaluate the persistence
f immune memory in subjects who had lost circulating anti-HBs
ntibodies. All 8 subjects in the 2-dose group and 10 of the 11 sub-
ects in the 3-dose group mounted an anamnestic response and
 300–900 fold increase in anti-HBs antibody GMCs was recorded
ne month post-challenge. This response to the challenge dose sug-
ests persistence of immune memory in almost all subjects, even
hen circulating antibodies have disappeared. These ﬁndings are
upported by those from a study conducted in Canada, where more
han 99% subjects maintained good immune memory and boost-
bility despite having had initial titres lower than the cut-off 15
ears after adolescent vaccination with a monovalent hepatitis B
accine [17]. Similar ﬁndings have also been observed for monova-
ent hepatitis B vaccines in studies assessing boostability after 5–20
ears following childhood immunisation [19–22].
Our results suggest that maintaining anti-HBs antibody concen-
rations above cut-off may  not be required for protection against
epatitis B infection as individuals can mount an anamnestic
esponse after exposure to hepatitis B even in the absence of
etectable antibodies at the time of exposure [18,19]. There is an
ngoing debate on whether the hepatitis B immunogenicity can
e effectively restored in subjects with anti-HBs titres below the
eﬁned protective level if they have not received a booster dose
12,17,18]. Most follow-up studies suggest that booster doses are
robably not necessary in immunocompetent subjects because of
he effective secondary (anamnestic) responses generated from
emory B cells [19,23]. For example, a study from China concluded
hat irrespective of the vaccination regimens, subjects who  develop
n adequate anti-HBs response after primary vaccination do not
equire booster dosing for at least 18 years [12]. As previously
bserved [18], a challenge dose of monovalent hepatitis B appeared
o be safe and well tolerated in all the subjects. (2016) 2686–2691
5. Conclusion
This study provided a unique opportunity to evaluate the pro-
tective capacity of two different vaccination schedules well into
adulthood, up to 15 years after primary vaccination during adoles-
cence. This is the ﬁrst study to compare the long-term persistence
and immune memory after either 2 doses of the adult or 3 doses of
the paediatric vaccine for such an extended period. The main limita-
tion of this type of study is loss to follow-up. However in our study,
feasibility of an extended follow-up was indicated by a reason-
ably high percentage of subjects returning for blood sampling (at
Year 10: 76% and at Year 15: 70%). The present study conﬁrms that
the combined hepatitis A and B vaccine is equally immunogenic
and safe in adolescents when administered as the standard 3-
dose paediatric regimen or as 2-dose of the adult strength vaccine.
The 2-dose regimen has the potential for higher vaccine coverage,
greater convenience, reduced costs and fewer medical visits [24].
The 2-dose regimen can also prove useful for catch-up vaccina-
tion programmes for older children and teenagers, and has already
been implemented in many European countries to protect high risk
individuals [25].
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